trofinetide FDA approval date

The FDA approved trofinetide on 10 Mar 2023.

FDA approval date
10 Mar 2023

Drug identity checked against registry records

Included trials

TrialSponsorPhaseStatusPrimary completion
Open-Label Extension Study of Trofinetide for Rett SyndromeNCT04776746ACADPhase 3Terminated2023-06-30Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-03-10DaytrofinetideFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA217026", "applicant_as_listed_by_fda": "ACADIA PHARMS INC", "brand_names": ["DAYBUE"], "active_ingredients": ["TROFINETIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230310", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026